

CLAIMS

1. Use of an EGFR TKI in the manufacture of a medicament for the treatment of non-small cell lung cancer in a human patient, wherein the EGFR TKI is to be administered in combination with an AKT inhibitor, wherein the EGFR TKI is osimertinib or a pharmaceutically acceptable salt thereof and the AKT inhibitor is capivasertib or a pharmaceutically acceptable salt thereof.
2. The use as claimed in claim 1, wherein the administration of the EGFR TKI and the AKT inhibitor is separate, sequential, or simultaneous.
3. The use as claimed in claim 1 or 2, wherein the non-small cell lung cancer is an EGFR mutation-positive non-small cell lung cancer.
4. The use as claimed in claim 3, wherein the EGFR mutation-positive non-small cell lung cancer comprises an activating mutation in EGFR selected from exon 19 deletions and L858R substitution mutations.
5. The use as claimed in claim 3 or claim 4, wherein the EGFR mutation-positive non-small cell lung cancer comprises a T790M mutation.
6. The use as claimed in any one of claims 1 to 4, wherein the human patient is an EGFR TKI-naïve human patient.
7. The use as claimed in any of the previous claims, wherein the cancer comprises a PIK3CA mutation.
8. The use as claimed in any of the previous claims, wherein the cancer is PTEN deficient.
9. The use as claimed in any one of claims 1 to 5, 7 or 8, wherein the human patient's disease has progressed during or after previous EGFR TKI treatment.

10. The use as claimed in claim 9, wherein the EGFR TKI is osimertinib or a pharmaceutically acceptable salt thereof and the human patient's disease has progressed during or after previous treatment with a different EGFR TKI.